Coloplast A/S (OTCMKTS:CLPBY) Trading Down 4.5% – What’s Next?

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) shares were down 4.5% during trading on Tuesday . The company traded as low as $6.28 and last traded at $6.32. Approximately 13,134 shares changed hands during trading, a decline of 98% from the average daily volume of 582,739 shares. The stock had previously closed at $6.6170.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CLPBY. Kepler Capital Markets raised shares of Coloplast A/S to a “strong-buy” rating in a research note on Wednesday, May 20th. Sanford C. Bernstein raised shares of Coloplast A/S to a “hold” rating in a research report on Wednesday, January 28th. Finally, The Goldman Sachs Group downgraded shares of Coloplast A/S from a “hold” rating to a “strong sell” rating in a research note on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Coloplast A/S presently has an average rating of “Hold”.

Coloplast A/S Trading Down 0.2%

The company has a market cap of $14.20 billion, a P/E ratio of 45.00, a P/E/G ratio of 2.00 and a beta of 0.15. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.30 and a quick ratio of 0.81. The stock’s 50-day moving average is $6.59 and its two-hundred day moving average is $7.79.

Coloplast A/S (OTCMKTS:CLPBY) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.09 by $0.01. The firm had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.11 billion. Coloplast A/S had a net margin of 7.46% and a return on equity of 31.96%. As a group, equities research analysts predict that Coloplast A/S Sponsored ADR will post 0.4 earnings per share for the current fiscal year.

Coloplast A/S Company Profile

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.